Cargando…
A Phase 4, Open-Label, Single-Arm Study Assessing the Efficacy and Safety of Ivabradine in African American Patients with Heart Failure and Reduced Ejection Fraction
INTRODUCTION: There are limited data on ivabradine therapy in black patients and none in African Americans. We performed an open-label, prospective study at two centers in the United States. African American patients with heart failure (HF) (N = 30), left ventricular ejection fraction ≤ 35%, and in...
Autores principales: | Lanfear, David E., Neaton, Kelsey R., Lu, Chen, Liu, Yimeng, Dent-Acosta, Ricardo E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584707/ https://www.ncbi.nlm.nih.gov/pubmed/32808163 http://dx.doi.org/10.1007/s40119-020-00196-1 |
Ejemplares similares
-
Role of Ivabradine in Patients with Heart Failure with Preserved Ejection Fraction
por: Nadeem, Muhammad, et al.
Publicado: (2020) -
Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
por: Lee, Ying‐Hsiang, et al.
Publicado: (2021) -
Effect of ivabradine on ventricular arrhythmias in heart failure patients with reduced ejection fraction
por: Pay, Levent, et al.
Publicado: (2023) -
Ivabradine in heart failure patients with reduced ejection fraction and history of paroxysmal atrial fibrillation
por: Lin, Yu‐Sheng, et al.
Publicado: (2022) -
The role of Ivabradine in Diastolic Heart Failure with preserved Ejection Fraction. A Doppler-Echocardiographic study
por: Cacciapuoti, Federico, et al.
Publicado: (2017)